Zentalis Pharmaceuticals, Inc. (ZNTL)
Market Cap | 253.52M |
Revenue (ttm) | 40.56M |
Net Income (ttm) | -218.96M |
Shares Out | 71.01M |
EPS (ttm) | -3.33 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,296,751 |
Open | 4.220 |
Previous Close | 4.190 |
Day's Range | 3.435 - 4.220 |
52-Week Range | 3.435 - 29.030 |
Beta | 1.83 |
Analysts | Buy |
Price Target | 13.14 (+268.07%) |
Earnings Date | Aug 7, 2024 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is $13.14, which is an increase of 268.07% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/c/d/press3-2506424.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are ...
![](https://cdn.snapi.dev/images/v1/s/q/press13-2505720.jpg)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molec...
![](https://cdn.snapi.dev/images/v1/g/x/press9-2503932.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such investors ...
![](https://cdn.snapi.dev/images/v1/g/b/press15-2484960.jpg)
Investigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLC
ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL) complied with federal securities la...
![](https://cdn.snapi.dev/images/v1/o/3/biotech15-2484381.jpg)
Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Tuesday, Zentalis Pharmaceuticals Inc ZNTL announced that the FDA has placed a partial clinical hold on the following studies of azenosertib:
![](https://cdn.snapi.dev/images/v1/g/z/biotech14-2484230.jpg)
US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop
Zentalis Pharmaceuticals said on Tuesday the U.S. Food and Drug Administration has placed a partial clinical hold on three studies testing its cancer drug, following the death of two trial participant...
![](https://cdn.snapi.dev/images/v1/h/k/press20-2483983.jpg)
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, ...
![](https://cdn.snapi.dev/images/v1/b/a/conf17-2453268.jpg)
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
![](https://cdn.snapi.dev/images/v1/w/p/press7-2451164.jpg)
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
![](https://cdn.snapi.dev/images/v1/i/k/conf3-2446501.jpg)
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators
![](https://cdn.snapi.dev/images/v1/q/l/conf5-2428939.jpg)
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...
![](https://cdn.snapi.dev/images/v1/r/l/press1-2414202.jpg)
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025
![](https://cdn.snapi.dev/images/v1/7/1/press2-2353039.jpg)
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of car...
![](https://cdn.snapi.dev/images/v1/y/i/conf17-2297989.jpg)
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiate...
![](https://cdn.snapi.dev/images/v1/u/9/press11-2295385.jpg)
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer ty...
![](https://cdn.snapi.dev/images/v1/a/b/press1-2272963.jpg)
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiate...
![](https://cdn.snapi.dev/images/v1/r/8/press20-2244023.jpg)
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D.
![](https://cdn.snapi.dev/images/v1/l/7/press14-2221545.jpg)
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharma...
![](https://cdn.snapi.dev/images/v1/3/f/press18-2219874.jpg)
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
BOTHELL, Wash. & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worl...
![](https://cdn.snapi.dev/images/v1/1/w/press3-2219602.jpg)
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharma...
![](https://cdn.snapi.dev/images/v1/6/g/press20-2210771.jpg)
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Phar...
![](https://cdn.snapi.dev/images/v1/q/h/press12-2194061.jpg)
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Phar...
![](https://cdn.snapi.dev/images/v1/m/v/press17-2181240.jpg)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharm...
![](https://cdn.snapi.dev/images/v1/v/e/press10-2168342.jpg)
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Phar...
![](https://cdn.snapi.dev/images/v1/x/l/press10-2166576.jpg)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Phar...